Even as obesity and diabetes heavyweights Eli Lilly and Novo Nordisk command headlines with their global manufacturing expansions, Boehringer Ingelheim is getting in on the action.
Thursday, Boehringer Ingelheim pledged 120 million euros ($131 million) to expand a plant in Koropi, Greece, to crank out more doses of new and existing medicines.
